A look back -- and forward

It's been a busy week here at the Life Sciences group. FierceBiotech's report from Rodman & Renshaw senior biotech analyst Simos Simeonidis delivered some remarkable readership numbers, indicating a real interest in upcoming events. FiercePharma's special report on the Top 15 Bestselling Drugs of 2008 produced eye-opening results--the best week that publication has ever had. And our new FiercePharmaManufacturing, written by George Miller, continues to build a solid audience with in-depth coverage of the field. If you have an interest in the drug manufacturing scene, you'll want to sign up for the report.

We have a lot more coming. This fall we'll be taking a look back at the companies recognized in the Fierce 15 from 2003 through 2008 and updating you on their track records. Given the high-risk, high-reward nature of this business, I expect we'll see some big successes, some notable failures and more than a few acquisitions. We'll also be examining the top economic development achievers in biotech for Europe and Asia. We're getting ready to map out an editorial schedule for 2010, so drop me a line if you have anything to suggest.

In the meantime we'll be taking a three-day weekend to celebrate Labor Day. We hope you enjoy your time off as well. - John Carroll

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.